Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 10/20 | 0.62 |
| ▸ | QDPR | P09417 | 3/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186127 | 0.80 | SIGMAR1 (0.65) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| SCHEMBL415545 | 0.78 | SIGMAR1 (1.00) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| Bromide SCHEMBL11385943 | 0.77 | SIGMAR1 (0.96) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL446973 | 0.77 | HTR2C (1.00) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| SCHEMBL2356913 | 0.76 | HTR2C (0.61) | SIGMAR1HTR2CQDPRHTR6DRD2 | |
| SCHEMBL19998281 | 0.75 | HTR2C (0.66) | SIGMAR1HTR2CQDPRHRH3HTR2A | |
| SCHEMBL1199051 | 0.75 | HTR2C (1.00) | SIGMAR1HTR2CQDPRHRH3HTR2A | |
| SCHEMBL8380936 | 0.75 | QDPR (1.00) | SIGMAR1HTR2CQDPR | |
| SCHEMBL532892 | 0.75 | HTR2C (0.66) | SIGMAR1HTR2CQDPRHTR2AHTR6 | |
| SCHEMBL3899585 | 0.75 | SIGMAR1 (0.92) | SIGMAR1HTR2CQDPRHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| US-8507505-B2 | Dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2013-08-13 | — | — | US | disclosed |
| EP-2376493-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. | 2011-10-06 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2010067886-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
| CN-101001842-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | SIGMAR1 724/4885HTR2C 2144/4885QDPR 2321/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | SIGMAR1 724/4885HTR2C 2144/4885QDPR 2321/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | SIGMAR1 724/4885HTR2C 2144/4885QDPR 2321/4885 |
| US-20110243891-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE2, WEE1, RPS6KA1 | SIGMAR1 1974/4885HTR2C 2354/4885QDPR 3062/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | SIGMAR1 724/4885HTR2C 2144/4885QDPR 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.